Remedy Cell and Qureight partner to add deep learning to RC-0315 Phase 1b IPF study

Remedy Cell, a biopharmaceutical company engaged in clinical-stage research, is pushing boundaries in the treatment of fibrotic diseases. Headquartered in Haifa, Israel, the company is focused on developing innovative therapies derived from cells to combat complex fibrotic conditions. In a strategic move, Remedy Cell has teamed up with Qureight Ltd, a Core Imaging Laboratory based in Cambridge, England, to explore the mechanism of RC-0315, a promising therapeutic agent aimed at addressing idiopathic pulmonary fibrosis (IPF).

The partnership targets a primary goal: validating RC-0315's mechanism within the confines of a Phase 1b clinical study. This study primarily aims to assess the safety and tolerability of the drug. As part of its exploratory objectives, the study will investigate the impact RC-0315 has on disease pathology. This will be measured using imaging techniques and biomarker analysis from bronchoalveolar lavage and plasma samples. The drug's distinctive therapeutic capability is rooted in its multi-target approach, which offers regenerative possibilities for addressing fibrotic diseases.

Qureight, utilizing its advanced deep-learning imaging platform, will provide precise analytical capabilities to observe specific lung regions and monitor the effects of RC-0315. This technology will enable a comprehensive understanding of localized changes within the lungs, offering insights into the drug's impact on airways, fibrosis, and blood vessels.

IPF is a particularly severe and complex interstitial lung disease affecting roughly three million individuals worldwide. This condition is marked by the progressive stiffening and thickening of lung tissue due to excessive collagen buildup, leading to a gradual decline in lung function. Patients often face severe respiratory challenges and a diminished quality of life, with a median survival rate of only two to five years post-diagnosis. Despite the profound implications of IPF, current treatment options remain insufficient, thereby highlighting the need for pioneering approaches.

RC-0315 emerges as a potential candidate to address this unmet clinical need. It offers a promise of repairing lung tissue and restoring pulmonary function through its novel multifactorial, multi-proteinacious properties. By targeting multiple IPF-associated sites, RC-0315 leverages several active proteins to engage lung tissue molecular targets, resulting in Ligand-Receptor Interactions that underpin its regenerative capabilities.

Qureight's role in integrating its deep-learning technology into the clinical study is pivotal. The company will deliver comprehensive imaging core lab services, covering site qualification, data management, quality control, and AI-driven image analysis. With RC-0315's unique application method, involving direct instillation into specific lung segments via bronchoscopy, Qureight's AI techniques will scrutinize sub-sections of the lungs for localized changes. This novel strategy promises a more precise quantification of lung segments, furnishing essential data for evaluating RC-0315's efficacy and advancing the development of effective IPF treatments.

Ayelet Dilion Mashiah, CEO of Remedy Cell, expressed enthusiasm about the collaboration, highlighting the company's progress from laboratory to clinical trials. She underscored the value of working with Qureight to deepen the understanding of RC-0315's mechanism and enhance the Phase 1b trial outcomes.

Dr. Muhunthan Thillai, CEO of Qureight, emphasized the significance of their AI-driven imaging analysis. He pointed out that focusing on localized lung changes, rather than traditional whole-lung assessments, can yield detailed insights into the treatment's effects on airways, fibrosis, and blood vessels. This approach could accelerate the development of more effective therapies for IPF patients.

Founded in 2018, Qureight is rapidly expanding its reach from its Cambridge headquarters. The Core Imaging Laboratory deploys its technology globally, offering a platform compliant with GDPR, HIPAA, and NHS Digital standards. Remedy Cell, on the other hand, is known for its ARcS platform, which delivers multi-target solutions for complex fibrotic conditions, with RC-0315 being its lead product that has shown potential in preclinical studies to repair lung tissue and restore function.